Previous 10 | Next 10 |
FLORHAM PARK, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a poster presentation at the up...
LM Funding America (NASDAQ: LMFA ) +83% . More news on: LM Funding America, Inc., Myomo, Inc., Electrameccanica Vehicles Corp., Stocks on the move, , Read more ...
FLORHAM PARK, N.J., July 01, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has appointed Dr. John ...
Fuwei Films (NASDAQ: FFHL ) +66% on Q1 results . More news on: Fuwei Films (Holdings) Co., Ltd., Translate Bio, Inc., Recon Technology, Ltd., Stocks on the move, , Read more ...
The European Patent Office issues a composition of matter patent to Cellectar Biosciences ( CLRB -5.8% ) covering the use of phospholipid ether (PLE) analogs as cancer-targeting drug vehicles. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Read more ...
FLORHAM PARK, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the European Patent Office...
Cellectar Biosciences (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, has closed an underwritten public offering for gross proceeds of $20.0 million. According to the update, the offeri...
IZEA Worldwide (NASDAQ: IZEA ) +79% . More news on: IZEA Worldwide, Inc., Second Sight Medical Products, Inc., Immuron Limited, Stocks on the move, , Read more ...
Cellectar Biosciences (NASDAQ: CLRB ) has closed its public offerin g of ~14.6M common shares and accompanying Series H warrants to purchase ~8.7M shares at $1.2075. It also issued ~2.8M pre-funded warrants. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, , Stocks on th...
FLORHAM PARK, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the closing of its previously announced un...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...